TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of recurrent or refractory pleomorphic sarcoma
Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Treatment options for recurrent or refractory pleomorphic sarcoma include the following:
Pembrolizumab.
The Sarcoma Alliance for Research through Collaboration conducted a phase II trial of the checkpoint inhibitor pembrolizumab in patients aged 18 years and older with recurrent soft tissue sarcoma.[155][Level of evidence C3]
Source links and citations
Seven of 40 patients (18%) with soft tissue sarcoma had an objective response.
Four of ten patients (40%) with undifferentiated pleomorphic sarcoma, two of ten patients (20%) with liposarcoma, and one of ten patients (10%) with synovial sarcoma had objective responses.
No patients with leiomyosarcoma (n = 10) had an objective response.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice